Late last month the China Food and Drug Administration (CFDA) began mandating that drug registration applicants self-inspect and verify clinical data to ensure that it’s authentic and reliable.
CRO Quintiles on Friday announced the pricing of a secondary public offering of 7,000,000 shares of its common stock at a price to the public of $77.85 per share, which is about $1 more per share than what the stock was selling for on Friday.
CDMO (contract development and manufacturing organization) Xcelience has made a structured cash investment in Pennsylvania-based contract manufacturer Powdersize, which specializes in milling, micronization and powder size classification.
Contract research organization Charles River Laboratories has extended its initial three-year strategic partnership with AstraZeneca for an additional five years.
Beginning Sept. 30, Massachusetts-based CRO (contract research organization) Parexel will lay off as many as 125 of the 450 employees it brought on from GlaxoSmithKline (GSK) in North Carolina late last year, according to a North Carolina WARN report obtained by Outsourcing-Pharma.com.